Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
the two edge sword will catch up to JPMorgan sooner or later..
it might not today but however loading area..
wow nite has alot of shares.. need take him out..
nite on both sides of the trade..
SAVW hit bottom at .0038 bounce from here..
wow cheap.. thanks.. savw
looks thin now nite is almost gone
is nite shorting? or buying
Pennyland Today? SAVW
Float 28,872,537
RSI cooling down SAVW
psychological test .007
strong resistance at .007 savw
big time!!!!!!!!!!!
getting slap around baby .006..
Blue skies.. Break out..!!!!! SAVW
OMG huge!!!! SAVW
SAVW break out!!!!!!!!!!!!!
you did not missed it.. with a little more buying power we have blue skies after .006
SAVW doing break out mode after .006
we might break through the .006 and .007 today!!! SAVW
MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) ("MultiCell") today announced that it entered into a sponsored research agreement with University Health Network pursuant to which Anand Ghanekar, M.D., Ph.D., of the University Health Network's Toronto General Hospital, will direct research activities relating to the evaluation of MultiCell's product candidates MCT-465 and MCT-485, in in vitro models for the treatment of primary liver cancer. The mechanism of action of MCT-465 and MCT-485 and their potential selective effect on liver cancer stem cells will also be evaluated.
The role of liver stem cells in the carcinogenic process has led researchers to hypothesize that primary liver cancer arises by maturation arrest of liver stem cells. While progress has been made in developing cancer therapies that result in cytoreduction, the control of cancer over a longer interval and especially of metastatic disease remains a key goal. Cancer stem cells are believed to be responsible for cancer relapse by being less sensitive to conventional therapies. MultiCell owns exclusive rights to several issued U.S. patents and corresponding foreign patents related to the isolation and differentiation of liver stem cells.
Primary liver cancer resulting from Hepatitis B and Hepatitis C infection is the most common cancer in the world with more than 1 million new cases diagnosed each year. Primary liver cancer is rarely discovered early and often does not respond to treatment.
"We are pleased to have the opportunity to work with Dr. Ghanekar and his colleagues at Toronto General Hospital," said W. Gerald Newmin, Chairman and Chief Executive Officer of MultiCell. "Dr. Ghanekar is one of the leading researchers in the field of liver cancer, and we are hopeful MCT-465 and MCT-485 will prove effective when evaluated in models of primary liver cancer," Mr. Newmin stated.
About MultiCell Technologies, Inc.
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer. For more information about MultiCell Technologies, please visit http://www.multicelltech.com.
About University Health Network
University Health Network, consisting of Toronto General Hospital, Toronto Western Hospital and Princess Margaret Hospital, is one of Canada's largest research hospitals. Among many discoveries, researchers at University Health Network were first to discover the existence of cancer stem cells. Primary funding for the University Health Network comes from Canada's Ontario Ministry of Health. For more information about the University Health Network, please visit http://www.uhn.ca
nice buys coming in
ask above the selling price they will get you covered
ask above the selling price they will get you covered
ask above the selling price they will get you covered
WTF blast off?
Will be adding more Monday TSTRQ
rare chance to get in at these prices.. TSTRQ
TSTRQ bottom in... will run on more volume to the upside..
just as expected DTRO is full of power.. the game has just began.. GL
Brav chart looks pretty impressive..
The all-cash deal was attractive to TerreStar in part because it provided enough money to let the company pay down its secured debt, according to Preis.
TerreStar filed court papers on Wednesday asking Lane to let it repay $1.26 billion owed to secured creditors before the end of September, rather than wait until the deal closes and incur interest at the rate of $46 million a quarter.
The case is in re: TerreStar Networks Inc, U.S. Bankruptcy Court, Southern District of New York, No. 10-15446.
____________________________________________________________________________________________________________________________________
we will start knowing before the end of Sept.
same company:
TerreStar Networks (www.terrestar.com), a majority owned subsidiary of TerreStar Corporation (TSTRQ), plans to offer a reliable and secure satellite terrestrial mobile broadband network that will provide voice, data and video services dedicated to helping solve the critical communication and business continuity challenges faced by government, emergency responders, enterprise businesses and rural communities. TerreStar expects to offer next generation mobile communications through a network of partners and service providers to users who need "anywhere" coverage throughout the United States and Canada.
Conversation about terrestar please dont delete:
same company terrestar corp.
ABBA what a loser.. we move up..
staircase action goin on
do us a favor keep on posting :)
very happy to hold.. looking damn good TSTRQ